Loading
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
Previous close
$7.36
−$0.20 · -2.65%
Pre-market
$7.26
−$0.10 · -1.36%
Sep 9, 4:00 AM ET
Regular session · ET · Market data may be delayed.
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
Day range
Current $7.36
52-week range
Current $7.36
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
30
Expensive
Sentiment
69
Bullish
Risk
52
Elevated Risk
Momentum
49
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
Day range
Current $7.36
52-week range
Current $7.36
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | — | 1.3M USD | — | — |
| Gross profit | — | — | −1.3M USD | — | — |
| Research and development | 90.3M USD | 73.3M USD | 63.94M USD | 42.24M USD | 25.16M USD |
| Selling, general, and administrative | 22.49M USD | 22.81M USD | 19.76M USD | 18.06M USD | 10.09M USD |
| Operating expenses | 112.79M USD | 96.12M USD | 83.7M USD | 60.3M USD | 35.25M USD |
| Interest income | 6.63M USD | 9.43M USD | 8.59M USD | 1.86M USD | 13K USD |
| Depreciation and amortization | 1.13M USD | 1.22M USD | 1.3M USD | 1.18M USD | 831K USD |
| Operating income | −112.79M USD | −96.12M USD | −84.99M USD | −60.3M USD | −35.25M USD |
| Net income | −106.19M USD | −86.92M USD | −76.41M USD | −58.76M USD | −35.25M USD |
Company facts updated Sep 9, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$17.50
137.77% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI20.75M0.00%2.3T USD0.03%$377.6-0.56%
iShares Russell 2000 ETFIWM8.5M0.01%80.51B USD0.19%$294.67-0.45%
Vanguard Extended Market ETFVXF7.95M0.01%93.7B USD0.05%$241.35-0.54%
iShares Biotechnology ETFIBB3.56M0.03%10.73B USD0.44%$207.33-2.17%
iShares Russell 2000 Growth ETFIWO2.89M0.02%14.7B USD0.24%$377.11-0.11%
Fidelity Enhanced Small Cap ETFFESM2.39M0.04%6.49B USD0.28%$47.09-0.57%
Schwab International Small-Cap Equity ETFSCHC2.23M0.04%5.77B USD0.06%$51.40-0.43%
Vanguard Health Care ETFVHT1.98M0.01%20.9B USD0.09%$314.61-2.19%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBiShares Russell 2000 Growth ETFIWOFidelity Enhanced Small Cap ETFFESMSchwab International Small-Cap Equity ETFSCHCVanguard Health Care ETFVHTAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
